Company overview
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing RANI with another company.
| Daily close (USD) | $0.79 |
| Market capitalization (USD) | $110,401,092.65 |
| Price / earnings (TTM) | Not reported |
| Price / book | 2.3 |
No matching rows. Clear the filter to see all records.
Read RANI's valuation metrics
Company size
Rani Therapeutics Holdings, Inc. Class A Common Stock's recorded market capitalization is $110,401,092.65. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
RANI's recorded price-to-book ratio is 2.3. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Rani Therapeutics Holdings, Inc. Class A Common Stock with Aurora
Use the snapshot above to ask a specific question about RANI. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow RANI's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.